Table 1.
Sample characteristics and overall orthostatic testing results of PD patients
| Demographic features | |
|---|---|
| n | 210 |
| Age (years) | 66.3 ± 10.6 |
| Gender m:f | 121:89 |
| Disease duration (years) | 6.7 ± 5.6 |
| Hoehn-Yahr score | 2.2 ± 0.8 |
| L-dopa equivalent dose (mg) | 492 ± 449 |
| Treatments, n (%) | |
| None | 15 (7%) |
| L-dopa | 170 (81%) |
| Dopamine agonists | 67 (32%) |
| MAO-B inhibitors | 80 (38%) |
| COMT inhibitors | 34 (16%) |
| Amantadine | 8 (4%) |
| Antihypertensives | 52 (25%) |
| Midodrine | 9 (4%) |
| Fludrocortisone | 22 (10%) |
| Orthostatic testing results | |
| SBP supine (mmHg) | 141.7 ±21.4 |
| DBP supine (mmHg) | 78.9 ± 11.2 |
| MBP supine (mmHg) | 99.9 ± 13.3 |
| HR supine (bpm) | 73.8 ± 9.7 |
| Supine hypertension | 44 (21%) |
| SBP standing 3-min (mmHg) | 122.2 ± 24.2 |
| DBP standing 3-min (mmHg) | 71.1 ± 14.5 |
| MBP standing 3-min (mmHg) | 87.9 ± 17.1 |
| HR standing 3-min (bpm) | 77.6 ± 11.2 |
| OH according to 20/10 mmHg | 105 (50%) |
| OH according to 30/15 mmHg | 64 (30%) |
| Symptomatic OH 20/10 mmHg | 33 (16%) |
| Symptomatic OH 30/15 mmHg | 28 (13%) |
| OH – fall in 20 and 10 mmHg | 43 (20%) |
| OH – fall in 30 and 15 mmHg | 31 (15%) |
| No OH with either criteria | 105 (50%) |
| Δ SBP (mmHg) | −19.4 ± 24.3 |
| Δ DBP (mmHg) | −7.9 ± 12.2 |
| Δ MBP (mmHg) | −11.9 ± 15.7 |
| Δ HR (bpm) | 3.8 ± 7.1 |
SBP: systolic blood pressure; DBP: diastolic blood pressure; MBP: mean blood pressure; HR: heart rate; OH: orthostatic hypotension.